Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies
Survival analysis using methods due to Kaplan and completed at least 2 yr follow-up and were prescribed sulphasalazine as their first disease-modifying antiMeier [1] is the recommended statistical technique for rheumatic drug (DMARD). We have focused attention use in cancer trials [2] . It is applied by analysing the on patients whose first DMARD was sulphasalazine distribution of patient survival times following their recruitment to a study. The analysis expresses these in terms of the proportion of patients still alive up to a given time following recruitment. In graphical terms, a plot of the proportion of patients surviving against time has a characteristic decline (often exponential ), the steepness of the curve indicating the efficacy of the treatment being investigated. The more shallow the survival curve, the more effective the treatment. KaplanMeier analysis can be used to test the statistical significance of differences between the survival curves associated with two different treatments.
In recent years, such survival analysis has found widespread application in the field of rheumatology [3] [4] [5] [6] [7] , being used to examine how long patients continue to tolerate a particular drug before either side-effects or lack of efficacy cause them to be switched to some other therapy. Although intuitively this seems analogous to oncology trial analysis, little research seems to have been done to confirm that survival analysis is a valid method to examine drug survivorship. In spite of this, survival analysis is becoming not only accepted within rheumatology, but dogmatically insisted upon. Indeed the authors have experienced harsh criticism from referees for not using it.
Of course, as a well-developed and investigated statistical method, the mathematical logic underlying KaplanMeier analysis is impeccable and we certainly would not dispute its value when applied in appropriate circumstances. However, just because a statistical technique has been shown to be mathematically sound and applicable to one clinical study does not make it universally applicable to all clinical studies.
Frustrated by numerous referees insisting on KaplanMeier analysis and concerned about the applicability of the method to drug survival, we have carried out some simple tests of the assumptions underlying the method. Sadly, it does not fare well. full ERAS patient group comprising 606 patients who © 2000 British Society for Rheumatology since it was the drug most commonly prescribed as a drug survival analysis to show that it is valid, given the evidence that there is one case where it is not. first DMARD within the ERAS cohort.
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